Eliminating graft-versus-host potential from T cell immunotherapeutic populations

Bone Marrow Transplantation

Volumn 18, Issue 2, 1996, Pages 415-420

  Rencher, S D ^a   Houston, J A ^a   Lockey, T D ^a   Hurwitz, J L ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Alloreactivity; Fluorescence activated cell sorter; Graft versus host disease; T cell immunotherapy; Viral disease

Indexed keywords

HLA ANTIGEN; MEMBRANE ANTIGEN;

ARTICLE; B LYMPHOBLAST; BONE MARROW PURGING; BONE MARROW TRANSPLANTATION; CELL CULTURE; CELL SELECTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LYMPHOBLASTOID CELL LINE; PRIORITY JOURNAL; RELAPSE; RISK; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GRAFT VS HOST DISEASE; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; T-LYMPHOCYTES;

EID: 0029831423     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Gale RP, Reisner Y. Graft rejection and graft-versus-host disease: mirror images. Lancet 1986; i: 1468-1470.
2. Prentice HG, Janossy G, Price-Jones L et al. Depletion of T lymphocytes in donor marrow prevents significant graft versus host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet 1984; i: 472-475.
3. Wingard JR. Advances in the management of infectious complications after bone marrow transplantation. Bone Marrow Transplant 1990; 6: 371-383.
4. Atkinson K. Reconstruction of the haemopoietic and immune systems after marrow transplantation. Bone Marrow Transplant 1990; 5: 209-226.
5. Blaise D, Gravis G, Maraninchi D. Long-term follow-up of T-cell depletion for bone marrow transplantation. Lancet 1993; 341: 51-52.
6. + cytotoxic T-cells against Epstein-Barr virus immortalized B-cell tumors in SCID mice. Transplantation 1994; 58: 629-633.
7. Rooney CM, Smith CA, Ng CYC et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
8. Helg C, Roux E, Beris P et al. Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant 1993; 12: 125-129.
9. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. New Engl J Med 1994; 331: 679-680.
10. Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New Engl J Med 1994; 330: 1185-1191.
11. Heslop HE, Brenner MK, Rooney CM et al. Administration of neo-R gene marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther 1994; 5: 381-397.
12. Riddell SR, Watanabe KS, Goodrich JM et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992; 257: 238-241.
13. Riddell SR, Greenberg PD. Therapeutic reconstitution of human viral immunity by adoptive transfer of cytotoxic T lymphocyte clones. In: Oldstone MBA (ed). Cytotoxic T-Lymphocytes in Human Viral and Malaria Infections. Springer-Verlag: Berlin, 1994, pp 9-34.
14. Burrows SR, Khanna R, Burrows JM, Moss DJ. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implication for graft-versus-host disease. J Exp Med 1994; 179: 1155-1161.
15. van Els CACM, D'Amaro J, Pool J et al. Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance. Immunogenet 1992; 35: 161-165.
16. Mavilio F, Ferrari G, Rossini S et al. Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood 1994; 83: 1988-1997.
17. Valteau-Couanet D, Cavazzana-Calvo M, Le Deist F et al Functional study of residual T lymphocytes after specific elimination of alloreactive cells by a specific anti-interleukin-2 receptor B-k chain immunotoxin. Transplantation 1993; 56: 1574-1576.
18. Antin JH, Bierer BE, Smith BR et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991; 78: 2139-2149.
19. Lenschow DJ, Bluestone JA. T cell co-stimulation and in vivo tolerance. Curr Opin Immunol 1993; 5: 747-752.
20. Freeman GJ, Gribben JG, Boussiotis VA et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993; 262: 909-911.
21. Van Gool SW, De Boer M, Ceuppens JL. The combination of anti-B7 monoclonal antibody and cyclosporin A induces alloantigen-specific anergy during a primary mixed lymphocyte reaction. J Exp Med 1994; 179: 715-720.